Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Cypher Stent Approval Includes Rapamune Label Change Monitoring

Executive Summary

Post-marketing commitments for Johnson & Johnson/ Cordis' Cypher sirolimus-eluting stent include close monitoring of labeling changes for Wyeth's sirolimus product Rapamune

You may also be interested in...



FDA Device Center Director Departs; Feigal Oversaw Approval Of Cypher Stent

CDRH Office of Device Evaluation Director Daniel Schultz, MD, will become acting director of FDA's device center May 1, replacing David Feigal, MD

FDA Device Center Director Departs; Feigal Oversaw Approval Of Cypher Stent

CDRH Office of Device Evaluation Director Daniel Schultz, MD, will become acting director of FDA's device center May 1, replacing David Feigal, MD

FDA Combo Approvals Could Follow Drug-Eluting Stent Template

FDA should use its approval of drug-eluting stents as the template for combination product approvals, attendees recommended at FDA's drug delivery workshop July 8 in Bethesda, Md

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel